Patients with a dysfunctional aortic heart valve who received a new, prosthetic valve through a minimally invasive procedure had similar outcomes at five years as those who underwent open-heart surgery, a new study shows.
Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program reached a significant milestone of performing over 4,000 transcatheter aortic valve replacement (TAVR) procedures with well over 650 in 2022 alone.
Hospitals without the highest stroke care designation may be missing strokes that occur after a common heart valve replacement procedure. Investigators found that comprehensive stroke centers reported significantly greater stroke rates after transcatheter aortic valve replacement (TAVR) than hospitals without the designation.
Mount Sinai researchers develop new risk stratification tool to optimize patient care and outcomes after TAVR
After reviewing national data from nearly 160,000 patients, Cedars-Sinai researchers found that transcatheter aortic valve replacement, or TAVR, could be a favorable option for some low-risk patients with bicuspid aortic stenosis. The findings were published in the Journal of the American Medical Association (JAMA).
NEWS STORIES IN THIS ISSUE:
-Study: Race and Ethnicity May Impact Prevalence and Treatment of Heart Valve Dysfunction
-Johns Hopkins Medicine Suggests Eliminating Nerve Cell Protein May Stop ALS, Dementia
-Researchers Tell Doctors to Avoid Routine Urinary Tests for Older Patients with Delirium
-Johns Hopkins Medicine Researchers Show How Air Pollution May Cause Chronic Sinusitis
-Researchers ID Location on Brain Protein Linked to Parkinson’s Disease Development
-COVID-19 News: The Return of Onsite Schooling — and How to Keep Your Kids Safe from COVID
Engineers have created 3D printed patient-specific models of the aorta that can aid presurgical planning and improve outcomes of minimally invasive valve replacement.
Only program in New York City to receive prestigious recognition
In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.
The Cardiovascular Research Foundation (CRF) will hold a free online seminar, “Get Heart Smart,” on August 24 hosted by Drs. Nisha Jhalani and Ajay Kirtane, renowned academic cardiologists from NewYork-Presbyterian/Columbia University Irving Medical Center. The seminar, part of a series of “Mini Med Schools” conducted by the CRF Women’s Heart Health Initiative, will focus on common heart disease symptoms, when to talk to your doctor, and when to seek emergency care.
The number of hospitals providing TAVR could double with changes to Medicare requirements. Researchers see reason for both excitement and concern.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement (TAVR), had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve. The study appears on the New England Journal of Medicine site.
PCR and TCT are proud to announce the creation of a new educational program: “Partners in Learning.” The first of its kind will focus on TAVI practitioners, taking place on 21-22 March 2020 in Sao Paulo, Brazil. It is the first ever stand-alone collaboration between TCT, PCR, and a regional core team of leading practitioners.
The Portico IDE study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems available in the United States.
Five-year results from the PARTNER 2A trial found that patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR.